Caroline Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Williams has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Tweddle
The Symptom Control and Palliative Care Team, The Royal Marsden NHS Foundation Trust, London, UK
1 shared publication - Anna-Marie Stevens
The Symptom Control and Palliative Care Team, The Royal Marsden NHS Foundation Trust, London, UK
1 shared publication - Catriona Rachel Mayland
Division of Clinical Medicine, University of Sheffield, Sheffield, UK
1 shared publication - Charlotte Benson
The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
1 shared publication - Christoph Becker
Medical Communication and Psychosomatic Medicine, University Hospital Basel and University of Basel, Switzerland
1 shared publication - Diane Laverty
London, UK
1 shared publication
Latest Publications
- 16 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-11
Prognostic understanding among patients with advanced cancer recently referred to an enhanced supportive care service: results from the cross-sectional ProgESC study
Purpose Prognostic understanding among patients with life-limiting diseases may help patient to make informed decisions about their care. The aim of our study was to assess the level of prognostic understanding among patients recently referred to an enhanced supportive care (ESC) service, to explore the factors associated with prognostic understanding and its association with patient-relevant outcomes. Methods Adult patients with metastatic cancer referred to the ESC service between November 13th, 2023, and August 31st, 2024, at the University College Hospital Macmillan Cancer Centre London were eligible and completed a structured online questionnaire. The primary endpoint was patients’ prognostic understanding assessed with the Prognosis and Treatment Perception Questionnaire. Secondary endpoints included symptoms of anxiety and depression, measured with the General Anxiety Disorder 2-item (GAD-2) and Patient Health Questionnaire-2 (PHQ-2), respectively. Results Out of 311 patients referred to the ESC, 91 were included in the study. Of these 91 patients, 34 (37.4%) were unaware of their incurable prognosis. In a regression model adjusted for age and gender, being in a relationship was significantly associated with good prognostic understanding (adjusted OR 2.75, 95% CI 1.11 to 6.8, p = 0.03). Patients who had a good prognostic understanding reported fewer symptoms of anxiety (16% vs. 36%; adjusted OR 0.32, 95% CI 0.12 to 0.88, p = 0.03) and depression (23% vs. 45%; adjusted OR 0.35, 95% CI 0.13 to 0.91, p = 0.03). Conclusion A significant proportion of patients with metastatic cancer were unaware that their cancer was not curable at referral to the ESC service. Improving prognostic understanding may help to reduce psychological distress and enhance emotional well-being, supporting better patient-centred ESC care.
- 16 April 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-11
Prognostic understanding among patients with advanced cancer recently referred to an enhanced supportive care service: results from the cross-sectional ProgESC study
Purpose Prognostic understanding among patients with life-limiting diseases may help patient to make informed decisions about their care. The aim of our study was to assess the level of prognostic understanding among patients recently referred to an enhanced supportive care (ESC) service, to explore the factors associated with prognostic understanding and its association with patient-relevant outcomes. Methods Adult patients with metastatic cancer referred to the ESC service between November 13th, 2023, and August 31st, 2024, at the University College Hospital Macmillan Cancer Centre London were eligible and completed a structured online questionnaire. The primary endpoint was patients’ prognostic understanding assessed with the Prognosis and Treatment Perception Questionnaire. Secondary endpoints included symptoms of anxiety and depression, measured with the General Anxiety Disorder 2-item (GAD-2) and Patient Health Questionnaire-2 (PHQ-2), respectively. Results Out of 311 patients referred to the ESC, 91 were included in the study. Of these 91 patients, 34 (37.4%) were unaware of their incurable prognosis. In a regression model adjusted for age and gender, being in a relationship was significantly associated with good prognostic understanding (adjusted OR 2.75, 95% CI 1.11 to 6.8, p = 0.03). Patients who had a good prognostic understanding reported fewer symptoms of anxiety (16% vs. 36%; adjusted OR 0.32, 95% CI 0.12 to 0.88, p = 0.03) and depression (23% vs. 45%; adjusted OR 0.35, 95% CI 0.13 to 0.91, p = 0.03). Conclusion A significant proportion of patients with metastatic cancer were unaware that their cancer was not curable at referral to the ESC service. Improving prognostic understanding may help to reduce psychological distress and enhance emotional well-being, supporting better patient-centred ESC care.
- Open Access
- 16 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (11) , 1-13
Assessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral “Triggers” Tool for outpatients with cancer
Purpose To evaluate the use, acceptability, and experience of a seven-item palliative care referral screening tool in an outpatient oncology setting. Methods A two-phase convergent parallel mixed-methods study. Patient participants who met any of the “Royal Marsden Triggers Tool” criteria were compared with those who did not in terms of demographic data, palliative care needs (Integrated Palliative Outcome Scale, IPOS) and quality of life indicators (EORTC-QLQ-C30). In-depth interviews were carried out with patients and oncology staff about their views and experience of the “Royal Marsden Triggers Tool”. Qualitative and quantitative data were triangulated at data interpretation. Results Three hundred forty-eight patients were recruited to the quantitative phase of the study of whom 53% met at least one of the Triggers tool palliative care referral criteria. When compared with patients who were negative using the Triggers tool, “Royal Marsden Triggers Tool” positive patients had a lower quality of life (EORTC QLQ-C30 Global Health Status scale (p < 0.01)) and a higher proportion had severe or overwhelming physical needs on IPOS (38% versus 20%, p < 0.001). Median survival of “Royal Marsden Triggers Tool” positive patients was 11.7 months. Sixteen staff and 19 patients participated in qualitative interviews. The use of the tool normalised palliative care involvement, supporting individualised care and access to appropriate expertise. Conclusion The use of a palliative care referral tool streamlines palliative care within oncology outpatient services and supports teams working together to provide an early holistic patient-centred service. Further research is needed to evaluate the effectiveness and feasibility of this approach.
- 16 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (11) , 1-13
Open AccessAssessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral “Triggers” Tool for outpatients with cancer
Purpose To evaluate the use, acceptability, and experience of a seven-item palliative care referral screening tool in an outpatient oncology setting. Methods A two-phase convergent parallel mixed-methods study. Patient participants who met any of the “Royal Marsden Triggers Tool” criteria were compared with those who did not in terms of demographic data, palliative care needs (Integrated Palliative Outcome Scale, IPOS) and quality of life indicators (EORTC-QLQ-C30). In-depth interviews were carried out with patients and oncology staff about their views and experience of the “Royal Marsden Triggers Tool”. Qualitative and quantitative data were triangulated at data interpretation. Results Three hundred forty-eight patients were recruited to the quantitative phase of the study of whom 53% met at least one of the Triggers tool palliative care referral criteria. When compared with patients who were negative using the Triggers tool, “Royal Marsden Triggers Tool” positive patients had a lower quality of life (EORTC QLQ-C30 Global Health Status scale (p < 0.01)) and a higher proportion had severe or overwhelming physical needs on IPOS (38% versus 20%, p < 0.001). Median survival of “Royal Marsden Triggers Tool” positive patients was 11.7 months. Sixteen staff and 19 patients participated in qualitative interviews. The use of the tool normalised palliative care involvement, supporting individualised care and access to appropriate expertise. Conclusion The use of a palliative care referral tool streamlines palliative care within oncology outpatient services and supports teams working together to provide an early holistic patient-centred service. Further research is needed to evaluate the effectiveness and feasibility of this approach.